Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say

Moderna (MRNA.O) should hit the lower end of its sales target for this year as it only needs to tap a small portion of the private market with its COVID vaccine to reach that goal, according to industry analysts.